Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review
Metalloproteinase PAPP - A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis. / Kashyap, Sonu; Hein, Kyaw Zaw; Chini, Claudia C.S.; Lika, Jorgo; Warner, Gina M.; Bale, Laurie K.; Torres, Vicente E.; Harris, Peter C.; Oxvig, Claus; Conover, Cheryl A.; Chini, Eduardo N.
I: JCI Insight, Bind 5, Nr. 4, e135700, 2020.Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Metalloproteinase PAPP - A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis
AU - Kashyap, Sonu
AU - Hein, Kyaw Zaw
AU - Chini, Claudia C.S.
AU - Lika, Jorgo
AU - Warner, Gina M.
AU - Bale, Laurie K.
AU - Torres, Vicente E.
AU - Harris, Peter C.
AU - Oxvig, Claus
AU - Conover, Cheryl A.
AU - Chini, Eduardo N.
PY - 2020
Y1 - 2020
N2 - Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic cause of end-stage renal disease (ESRD). The treatment options for ADPKD are limited. We observed an upregulation in several IGF-1 pathway genes in the kidney of Pkd1RC/RC mice, a model of ADPKD. Pregnancy-associated plasma protein A (PAPP-A), a metalloproteinase that cleaves inhibitory IGF binding proteins (IGFBPs), increasing the local bioactivity of IGF-1, was highly induced in the kidney of ADPKD mice. PAPP-A levels were high in cystic fluid and kidneys of humans with ADPKD. Our studies further showed that PAPP-A transcription in ADPKD was mainly regulated through the cAMP/CREB/CBP/p300 pathway. Pappa deficiency effectively inhibited the development of cysts in the Pkd1RC/RC mice. The role of PAPP-A in cystic disease appears to be regulation of the IGF-1 pathway and cellular proliferation in the kidney. Finally, preclinical studies demonstrated that treatment with a monoclonal antibody that blocks the proteolytic activity of PAPP-A against IGFBP4 ameliorated ADPKD cystic disease in vivo in Pkd1RC/RC mice and ex vivo in embryonic kidneys. These data indicated that the PAPP-A/IGF-1 pathway plays an important role in the growth and expansion of cysts in ADPKD. Our findings introduce a therapeutic strategy for ADPKD that involves the inhibition of PAPP-A.
AB - Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic cause of end-stage renal disease (ESRD). The treatment options for ADPKD are limited. We observed an upregulation in several IGF-1 pathway genes in the kidney of Pkd1RC/RC mice, a model of ADPKD. Pregnancy-associated plasma protein A (PAPP-A), a metalloproteinase that cleaves inhibitory IGF binding proteins (IGFBPs), increasing the local bioactivity of IGF-1, was highly induced in the kidney of ADPKD mice. PAPP-A levels were high in cystic fluid and kidneys of humans with ADPKD. Our studies further showed that PAPP-A transcription in ADPKD was mainly regulated through the cAMP/CREB/CBP/p300 pathway. Pappa deficiency effectively inhibited the development of cysts in the Pkd1RC/RC mice. The role of PAPP-A in cystic disease appears to be regulation of the IGF-1 pathway and cellular proliferation in the kidney. Finally, preclinical studies demonstrated that treatment with a monoclonal antibody that blocks the proteolytic activity of PAPP-A against IGFBP4 ameliorated ADPKD cystic disease in vivo in Pkd1RC/RC mice and ex vivo in embryonic kidneys. These data indicated that the PAPP-A/IGF-1 pathway plays an important role in the growth and expansion of cysts in ADPKD. Our findings introduce a therapeutic strategy for ADPKD that involves the inhibition of PAPP-A.
UR - http://www.scopus.com/inward/record.url?scp=85081645384&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.135700
DO - 10.1172/jci.insight.135700
M3 - Journal article
C2 - 31990681
AN - SCOPUS:85081645384
VL - 5
JO - JCI Insight
JF - JCI Insight
SN - 2379-3708
IS - 4
M1 - e135700
ER -